Active Choice Clinical Decision Support (CDS): Hepatocellular Carcinoma (HCC) Screening in Patients With Cirrhosis

Part of paid clinical trials in New York, New York.

Sponsor
NYU Langone Health
Study ID
NCT06624189
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Auto-pended bot liver ultrasound order — OTHER
    This alert prompt providers at the time of encounter to place appropriate imaging orders for hepatocellular carcinoma (HCC) screening in patients with cirrhosis.

Study Details

The research team will evaluate the effectiveness of an auto-pended bot liver ultrasound order that will prompt providers at the time of encounter to place appropriate imaging orders for hepatocellular carcinoma (HCC) screening in patients with cirrhosis.

Key Dates

Start date
Nov 20, 2024
Status verified
Feb 2026
Primary completion
Apr 24, 2026
Completion
Jul 24, 2026

Study Design

Enrollment
1,300 participants (estimated)

Arms

  • Arm: Intervention: Auto-pended bot liver ultrasound order
    Participants in the intervention group will receive an auto-pended bot liver ultrasound order that will prompt providers at the time of encounter to place appropriate imaging orders for hepatocellular carcinoma (HCC) screening.
  • Arm: Control: Usual Care
    Participants in the control group will not receive the auto-pended bot liver ultrasound order.

Primary Outcome Measure

Percentage of Participants for whom the Physician Completed Ordering of the Pending Liver Ultrasound [ Time Frame: Day 1 ]

Locations (1)

FacilityCityStateZIPSite coordinators
NYU Langone HealthNew YorkNew York10016-

Find similar trials in New York, NY

By condition
Liver cancer
By specialty
OncologyGI oncologyHepatology
By research site
NYU Langone Health· New York, NY

Related Studies